“For many years now, Aspire has been a tremendous institutional investor and financial partner to our Company and many of our successes to date are underscored by their unwavering support,” commented Leo Ehrlich, Chief Executive Officer at Innovation Pharmaceuticals. “Aspire’s new $30 million commitment combined with our cash on hand puts us in a strong financial position to continue our aggressive drug development strategies.”
Separately, the Company has filed all requisite documentation with the U.S. Securities and Exchange Commission (“SEC”) as part of a $75 million shelf registration.
$30 million plus $75 million= $105 million available in necessary.
Negotiate with big pharmaceuticals from a position of financial strength.